MiMedx Group (NASDAQ:MDXG) Price Target Raised to $12.00

Key Points

• Cantor Fitzgerald has raised the target price for MiMedx Group (NASDAQ:MDXG) from $11.00 to $12.00, suggesting a potential upside of 65.95% from its current price, while maintaining an "overweight" rating on the stock.
• Separately, Wall Street Zen has downgraded MiMedx Group from a "buy" rating to a "hold" rating as of July 18th.
• CEO Joseph H. Capper recently acquired 200,000 shares of MiMedx Group at an average price of $6.34 per share, increasing his ownership stake by 60.69%.

MiMedx Group (NASDAQ:MDXG - Free Report) had its price target upped by Cantor Fitzgerald from $11.00 to $12.00 in a research report released on Thursday,Benzinga reports. They currently have an overweight rating on the stock. Cantor Fitzgerald also issued estimates for MiMedx Group's FY2025 earnings at $0.25 EPS and FY2026 earnings at $0.33 EPS.

Separately, Wall Street Zen downgraded shares of MiMedx Group from a "buy" rating to a "hold" rating in a report on Friday, July 18th.

MiMedx Group Stock Down 0.1%

MDXG traded down $0.01 during trading on Thursday, hitting $7.15. 980,630 shares of the company's stock were exchanged, compared to its average volume of 696,110. The stock has a market cap of $1.06 billion, a P/E ratio of 34.05 and a beta of 1.79. The business's 50 day moving average is $6.44 and its two-hundred day moving average is $7.24. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a quick ratio of 3.90, a current ratio of 4.39 and a debt-to-equity ratio of 0.08.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. The company had revenue of $98.61 million for the quarter, compared to the consensus estimate of $90.79 million. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. As a group, equities analysts expect that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC grew its holdings in shares of MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company's stock worth $30,000 after purchasing an additional 1,892 shares during the last quarter. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group in the fourth quarter worth approximately $35,000. Virtus Advisers LLC bought a new position in shares of MiMedx Group in the first quarter worth approximately $40,000. Tower Research Capital LLC TRC grew its holdings in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after purchasing an additional 2,837 shares during the last quarter. Finally, Legato Capital Management LLC bought a new position in shares of MiMedx Group in the first quarter worth approximately $101,000. 79.15% of the stock is currently owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.